• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法国初级医疗保健中绝经后骨质疏松症患者的特征分析。

Characterisation of patients with postmenopausal osteoporosis in French primary healthcare.

作者信息

Blotman Francis, Cortet Bernard, Hilliquin Pascal, Avouac Bernard, Allaert François-André, Pouchain Denis, Gaudin Anne-Françoise, Cotté François-Emery, El Hasnaoui Abdelkader

机构信息

Rheumatology Department, Montpellier University Hospital, Montpellier, France.

出版信息

Drugs Aging. 2007;24(7):603-14. doi: 10.2165/00002512-200724070-00007.

DOI:10.2165/00002512-200724070-00007
PMID:17658910
Abstract

BACKGROUND

The public health burden of osteoporosis is high, principally because of increased risk of fractures and associated morbidity, handicap and mortality. Osteoporotic fracture prevention is therefore an important public health goal. General practitioners (GPs) play a key role in the management of osteoporosis, both in ensuring timely diagnosis and in providing treatment. Little information is available on standards of care for postmenopausal women with osteoporosis in general practice.

OBJECTIVES

The primary objective of this study was to describe risk factors and treatment in postmenopausal women with osteoporosis. Secondary objectives were to evaluate treatment compliance and to assess the impact of osteoporosis on quality of life.

METHODS

This observational, cross-sectional, pharmacoepidemiological study was performed in a primary-care setting in France. A random sample of GPs recruited postmenopausal women with a diagnosis of osteoporosis who had been followed by the investigator for at least 2 years. At inclusion, investigators completed a questionnaire providing information on patient age, osteoporosis duration, risk factors and treatment history. The first three patients recruited by each investigator completed a questionnaire providing information on sociodemographic features, osteoporosis treatments and quality of life. Treatment compliance was quantified using the Test d'Evaluation de l'Observance and quality of life evaluated using the 12-item Short Form Health Survey (SF-12).

RESULTS

Overall, 389 physicians included 3,097 patients, of whom 1,053 completed the patient questionnaire. Risk factors for osteoporotic fracture were identified in 2,148 patients (69.4%), most frequently personal or maternal antecedents of osteoporotic fracture and a low body mass index. Of these, 946 (44.0%) presented more than one risk factor. At the time of diagnosis, 629 patients (59.7%) presented fractures, which involved the vertebrae in 51.7% of cases, the wrist in 40.5% and the hip in 5.4%. Older patients were more likely to have fractures at the time of diagnosis and to have multiple fractures. After diagnosis, at least one new fracture occurred in 201 patients (19.2%). Multivariate logistic regression analysis identified age >70 years, diagnosis at least 10 years previously, diagnosis based on the presence of a fracture, biochemical and haematological evaluation at the time of diagnosis, and a change in osteoporosis treatment in the previous 2 years as being significantly associated with incident fracture risk. At inclusion, 1,019 patients (97.4%) were receiving treatment for osteoporosis, most frequently weekly bisphosphonates (71.6% of treatments). Most patients (81.0%) had been treated for at least 1 year. Treatment compliance was high in 61% of patients and low in <5%. Patient variables associated with high compliance were being retired, prescription of bisphosphonates and, among the bisphosphonate users, prescription of weekly formulations. SF-12 quality-of-life scores were low, ranging from 38.6 (energy/vitality) to 65.1 (social functioning) out of a possible maximum score of 100. Baseline variables associated with SF-12 physical component summary scores included age, height loss since menopause, diagnosis following a fracture, fracture incidence since diagnosis, time since diagnosis and treatment with bisphosphonates.

CONCLUSIONS

In this study of postmenopausal osteoporosis in the French primary healthcare setting, many women with osteoporosis were diagnosed following a fracture. Although most were treated with bone-consolidating drugs, compliance was suboptimal in a significant minority. Osteoporotic fracture was associated with reduced quality of life.

摘要

背景

骨质疏松症的公共卫生负担沉重,主要原因是骨折风险增加以及相关的发病率、残疾和死亡率。因此,预防骨质疏松性骨折是一项重要的公共卫生目标。全科医生(GPs)在骨质疏松症的管理中起着关键作用,包括确保及时诊断和提供治疗。关于全科医疗中绝经后骨质疏松症女性的护理标准,目前可用信息较少。

目的

本研究的主要目的是描述绝经后骨质疏松症女性的风险因素和治疗情况。次要目的是评估治疗依从性,并评估骨质疏松症对生活质量的影响。

方法

这项观察性、横断面、药物流行病学研究在法国的初级保健机构中进行。随机抽取的全科医生招募了诊断为骨质疏松症且由研究者随访至少2年的绝经后女性。纳入时,研究者完成一份问卷,提供患者年龄、骨质疏松症病程、风险因素和治疗史等信息。每位研究者招募的前三位患者完成一份问卷,提供社会人口学特征、骨质疏松症治疗和生活质量等信息。使用观察性评估测试对治疗依从性进行量化,并使用12项简短健康调查问卷(SF-12)对生活质量进行评估。

结果

总体而言,389名医生纳入了3097名患者,其中1053名完成了患者问卷。2148名患者(69.4%)被确定存在骨质疏松性骨折的风险因素,最常见的是个人或母亲有骨质疏松性骨折病史以及低体重指数。其中,946名(44.0%)存在不止一个风险因素。诊断时,629名患者(59.7%)出现骨折,其中51.7%的骨折累及椎体,40.5%累及腕部,5.4%累及髋部。年龄较大的患者在诊断时更易发生骨折且有多处骨折。诊断后,201名患者(19.2%)至少发生了一次新的骨折。多因素逻辑回归分析确定,年龄>70岁、诊断时间至少在10年前、基于骨折存在进行诊断、诊断时进行生化和血液学评估以及在过去2年中骨质疏松症治疗发生改变与新发骨折风险显著相关。纳入时,1019名患者(97.4%)正在接受骨质疏松症治疗,最常用的是每周一次的双膦酸盐类药物(占治疗的71.6%)。大多数患者(81.0%)已接受治疗至少1年。61%的患者治疗依从性高,<5%的患者依从性低。与高依从性相关的患者变量包括已退休、双膦酸盐类药物处方,在双膦酸盐类药物使用者中,还包括每周剂型的处方。SF-12生活质量评分较低,在满分100分的情况下,从38.6(精力/活力)到65.1(社会功能)不等。与SF-12身体成分综合评分相关的基线变量包括年龄、绝经后身高降低、骨折后诊断、诊断后骨折发生率、诊断时间以及双膦酸盐类药物治疗。

结论

在这项关于法国初级医疗环境中绝经后骨质疏松症的研究中,许多骨质疏松症女性是在骨折后被诊断出来的。尽管大多数患者接受了骨巩固药物治疗,但仍有相当一部分患者的依从性不理想。骨质疏松性骨折与生活质量下降相关。

相似文献

1
Characterisation of patients with postmenopausal osteoporosis in French primary healthcare.法国初级医疗保健中绝经后骨质疏松症患者的特征分析。
Drugs Aging. 2007;24(7):603-14. doi: 10.2165/00002512-200724070-00007.
2
Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.老年女性骨质疏松症抗吸收药物使用的趋势及决定因素
Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):685-95. doi: 10.1002/pds.1068.
3
Impact of recent fracture on health-related quality of life in postmenopausal women.近期骨折对绝经后女性健康相关生活质量的影响。
J Bone Miner Res. 2006 Jun;21(6):809-16. doi: 10.1359/jbmr.060301.
4
Low self-awareness of osteoporosis and fracture risk among postmenopausal women.绝经后女性对骨质疏松症和骨折风险的自我认知较低。
Arch Osteoporos. 2016 Dec;11(1):27. doi: 10.1007/s11657-016-0266-3. Epub 2016 Aug 8.
5
Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.法国初级医疗保健中骨质疏松症药物的依从性、持续性与骨折风险之间的关系:一项回顾性病例对照分析。
Clin Ther. 2008 Dec;30(12):2410-22. doi: 10.1016/j.clinthera.2008.12.019.
6
Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study.初级保健中骨质疏松症的患病率及治疗水平:澳大利亚骨健康研究
J Bone Miner Res. 2004 Dec;19(12):1969-75. doi: 10.1359/JBMR.040905. Epub 2004 Sep 13.
7
Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study.健康绝经后女性所有骨质疏松相关骨折的独立预测因素:OFELY研究
Bone. 2003 Jan;32(1):78-85. doi: 10.1016/s8756-3282(02)00919-5.
8
Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.绝经后女性未诊断出的低骨密度的识别与骨折结局:来自国家骨质疏松症风险评估的结果
JAMA. 2001 Dec 12;286(22):2815-22. doi: 10.1001/jama.286.22.2815.
9
Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment.绝经后骨质疏松症治疗患者的依从性和治疗满意度。骨质疏松症治疗的依从性。
BMC Womens Health. 2010 Aug 20;10:26. doi: 10.1186/1472-6874-10-26.
10
Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.原发性保健中 FRAX 的应用:绝经后妇女和老年男性的绝对骨折风险评估。
Postgrad Med. 2010 Jan;122(1):82-90. doi: 10.3810/pgm.2010.01.2102.

引用本文的文献

1
A systematic review of factors affecting medication adherence among patients with osteoporosis.骨质疏松症患者药物治疗依从性影响因素的系统评价
Osteoporos Int. 2018 Dec;29(12):2623-2637. doi: 10.1007/s00198-018-4759-3. Epub 2018 Nov 12.
2
The Prevalence of Osteopenia and Osteoporosis Among Malaysian Type 2 Diabetic Patients Using Quantitative Ultrasound Densitometer.使用定量超声骨密度仪评估马来西亚2型糖尿病患者中骨量减少和骨质疏松症的患病率。
Open Rheumatol J. 2018 Apr 25;12:50-64. doi: 10.2174/1874312901812010050. eCollection 2018.
3
Association between gastrointestinal events and osteoporosis treatment initiation in women diagnosed with osteoporosis in France: a retrospective analysis.

本文引用的文献

1
The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.给药频率对绝经后女性双膦酸盐治疗依从性和持续性的影响:美国、英国和法国研究的比较。
Clin Ther. 2006 Oct;28(10):1686-94. doi: 10.1016/j.clinthera.2006.10.013.
2
Prescreening tools to determine who needs DXA.用于确定谁需要进行双能X线吸收测定的预筛查工具。
Curr Osteoporos Rep. 2006 Dec;4(4):148-52. doi: 10.1007/s11914-996-0023-4.
3
Medication persistence with weekly versus daily doses of orally administered bisphosphonates.
法国骨质疏松症确诊女性胃肠道事件与开始骨质疏松症治疗之间的关联:一项回顾性分析。
BMC Musculoskelet Disord. 2016 Apr 30;17:195. doi: 10.1186/s12891-016-1041-8.
4
A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years.一项大型前瞻性欧洲队列研究,纳入了接受雷奈酸锶治疗且随访超过 3 年的患者。
Rheumatol Int. 2013 Sep;33(9):2231-9. doi: 10.1007/s00296-012-2594-y. Epub 2013 Mar 2.
5
MENOPOST--calcium and vitamin D supplementation in postmenopausal osteoporosis treatment: a descriptive cohort study.绝经后——钙和维生素 D 补充治疗绝经后骨质疏松症:描述性队列研究。
Osteoporos Int. 2013 Feb;24(2):559-66. doi: 10.1007/s00198-012-1999-5. Epub 2012 May 16.
6
Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France.法国绝经后骨质疏松症治疗中口服双膦酸盐药物不持续治疗的成本。
BMC Health Serv Res. 2011 Jun 25;11:151. doi: 10.1186/1472-6963-11-151.
7
Management of osteoporosis and associated quality of life in post menopausal women.绝经后妇女骨质疏松症及其相关生活质量的管理。
BMC Musculoskelet Disord. 2011 Jan 12;12:7. doi: 10.1186/1471-2474-12-7.
8
Patients' preferences for osteoporosis drug treatment: a discrete choice experiment.患者对骨质疏松症药物治疗的偏好:一项离散选择实验。
Osteoporos Int. 2008 Jul;19(7):1029-37. doi: 10.1007/s00198-007-0535-5. Epub 2008 Jan 8.
口服双膦酸盐每周剂量与每日剂量的用药持续性
Endocr Pract. 2006 Sep-Oct;12(5):522-8. doi: 10.4158/EP.12.5.522.
4
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.对全球骨质疏松性骨折的患病率及相关残疾情况的一项评估。
Osteoporos Int. 2006 Dec;17(12):1726-33. doi: 10.1007/s00198-006-0172-4. Epub 2006 Sep 16.
5
Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis?依从性、持续性、一致性:我们是否为骨质疏松症患者提供了最佳治疗?
Joint Bone Spine. 2006 Oct;73(5):e1-7. doi: 10.1016/j.jbspin.2006.02.006. Epub 2006 Jul 26.
6
[Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment].[口服双膦酸盐每日及每周给药用于骨质疏松症治疗的依从性]
Dtsch Med Wochenschr. 2006 Jun 2;131(22):1257-62. doi: 10.1055/s-2006-946559.
7
Impact of recent fracture on health-related quality of life in postmenopausal women.近期骨折对绝经后女性健康相关生活质量的影响。
J Bone Miner Res. 2006 Jun;21(6):809-16. doi: 10.1359/jbmr.060301.
8
Improving compliance and persistence with bisphosphonate therapy for osteoporosis.提高骨质疏松症双膦酸盐治疗的依从性和持续性。
Am J Med. 2006 Apr;119(4 Suppl 1):S18-24. doi: 10.1016/j.amjmed.2005.12.019.
9
Determinants of adherence to osteoporosis treatment in clinical practice.临床实践中骨质疏松症治疗依从性的决定因素。
Osteoporos Int. 2006;17(6):914-21. doi: 10.1007/s00198-006-0073-6. Epub 2006 Mar 15.
10
Compliance with treatment in osteoporosis patients--an ongoing problem.骨质疏松症患者的治疗依从性——一个持续存在的问题。
Aust Fam Physician. 2006 Mar;35(3):135-7.